Canaccord Genuity Reiterates a 'Buy' on Impax Laboratories (IPXL); Our Top Small Cap Pick is Catalyst Heavy

Article Stock Quotes (1) Comments (0)

Canaccord Genuity reiterates a 'Buy' on Impax Laboratories (NASDAQ: IPXL) price target of $29.00.

Analyst, Randall Stanicky, said, "We hosted meetings with Impax management for the second time in as many weeks as we look to stay close to the story. Our message remains consistent and unchanged – we see a catalyst-heavy near-term path with sentiment we think will continue to improve. The warning letter has cast a cloud on what we think is an inflection year for IPXL as several headwinds (warning letter, Adderall XR supply) are now likely to turn into upside drivers this year while the outlook for 2013 and beyond is still underestimated, in our view...IPXL remains our top small cap generic stock."

For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.

Shares of Impax Laboratories closed at $23.13 yesterday, with a 52 week range of $14.46-$28.75.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Upgrades Seagate (STX) to Buy; Sanmina (SANM) Cut to Sell, Flextronics (FLEX) & Fabrinet (FN) Cut to Hold
• Goldman Sachs Downgrades Aixtron (AIXG) to Neutral
• Topeka Capital Starts Atmel (ATML) at Buy

Create E-mail Alert Related Categories

Analyst Comments

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?